The in vivo pharmacological profile of eletriptan (UK-116,044): A potent and novel 5-HT(1B/1D) receptor agonist

European Journal of Pharmacology

Volumn 398, Issue 1, 2000, Pages 73-81

  Gupta, Paul ^a   Butler, Paul ^a   Shepperson, Nick B ^a   McHarg, Aileen ^a  

^a PFIZER INC   (United States)

Author keywords

Carotid artery blood flow; Coronary artery diameter; Eletriptan; Femoral artery blood flow; Neurogenic inflammation; Sumatriptan

Indexed keywords

ELETRIPTAN; PLASMA PROTEIN; SUMATRIPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTERY CONSTRICTION; ARTICLE; CAROTID ARTERY FLOW; CONTROLLED STUDY; CORONARY ARTERY; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DURA MATER; ELECTROSTIMULATION; FEMALE; MALE; NEUROGENIC INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; TRIGEMINAL NERVE; TRIGEMINUS GANGLION;

ANESTHESIA; ANIMALS; BLOOD FLOW VELOCITY; BLOOD PROTEINS; CAPILLARY PERMEABILITY; CORONARY CIRCULATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DURA MATER; ELECTRIC STIMULATION; FEMALE; FEMORAL ARTERY; HEMODYNAMIC PROCESSES; INDOLES; MALE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN; TRIGEMINAL GANGLION; TRYPTAMINES;

EID: 0034625501     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00240-5     Document Type: Article

References (52)

1. Arnold G., Reuter U., Kinze S., Wolf T., Einhaupl K.M. Migraine with aura shows gadolinium enhancement which is reversed following prophylactic treatment. Cephalalgia. 18:1998;644-646.
2. 1D-like receptors, and a comparison with grafted veins. Naunyn-Schmiedeberg's Arch. Pharmacol. 345:1992;500-508.
3. Bouchelet I., Cohen Z.V.I., Case B., Seguela P., Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol. 50:1996;219-223.
4. 1B receptor messenger RNA in rat brain and trigeminal ganglia. Br. J. Pharmacol. 108:1993;. 95 pp.
5. Buzzi M.G., Moskowitz M.A. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br. J. Pharmacol. 99:1990;202-206.
6. Buzzi M.G., Moskowitz M.A., Peroutka S.J., Byun B. Further characterisation of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. Br. J. Pharmacol. 103:1991;1421-1428.
7. Caekebeke J.F., Ferrari M.D., Zwetsloot C.P., Jansen J., Saxena P.R. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology. 42:1992;1522-1526.
8. 2-receptor agonist, U46619. Br. J. Pharmacol. 110:1993;360-368.
9. 2 receptor activation. Eur. J. Pharmacol. 161:1989;91-94.
10. Connor H.E., Bertin L., Gillies S., Beattie D.T., Ward P. Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia. 18:1998;392.
11. Delean A., Munson P.J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235:1978;E97-E102.
12. 1-like receptors in the reduction of porcine cranial arteriovenous anastomic shunting by sumatriptan. Br. J. Pharmacol. 102:1991;323-330.
13. Earl N.L., McDonald S.A., Lowy M.T. Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine. Cephalalgia. 19:1999;357.
14. Feniuk W., Humphrey P.P.A., Perren M.J. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br. J. Pharmacol. 96:1989;83-90.
15. Ferrari M.D. Treatment of migraine attacks with sumatriptan. N. Engl. J. Med. 325:1991;316-321.
16. Ferrari M.D., Saxena P.R. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol. Sci. 14:1993;129-133.
17. Friberg L., Olesen J., Iversen H.K., Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. J. Neurol. Neurosurg. Psychiatry. 338:1991;13-17. (see comments).
18. Giles H., Honey A., Edvinsson L., Selwod D., Cambridge D., Martin G.R. Preclinical Pharmacology of 4991W93, a potent inhibitor of neurogenic plasma protein extravasation. Cephalalgia. 19:1999;402.
19. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33:1993;48-56.
20. Goadsby P.J., Ferrari M.D., Olesen J., Stovner L.J., Senard J.M., Jackson N.C., Poole P.H. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology. 54(1):1999;156-163.
21. Goldstein D.J., Wang O., Saper J.R., Silberstein S.D., Mathew N.T. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a cross-over study. Cephalalgia. 17(7):1997;785-790.
22. Gupta P., Butler P., Ellis P., Grayson K., Land G.C., Macor J.E., Robson S.F., Wythes M.J., Shepperson N.B. The in vivo pharmacological profile of CP-122,288, a selective inhibitor of neurogenic inflammation. Br. J. Pharmacol. 116:1995;2385-2390.
23. 1B receptor. Eur. J. Pharmacol. 367:1999;283-290.
24. 1B/ID agonists and endopeptidase 24.11. Br. J. Pharmacol. 108:1993;331-335.
25. 1-like receptor. Cephalalgia. 12:1992;202-205.
26. Kaumann A.J., Parson A.A., Brown A.M. Human arterial constrictor serotonin receptors. Cardiovasc. Res. 27:1993;2094-2103.
27. 2 receptors in serotonin-induced contraction of human isolated coronary arteries. Circulation. 90:1994;1141-1153.
28. Lee W.S., Moussaoui S.M., Moskowitz M.A. Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br. J. Pharmacol. 112(3):1994;920-924.
29. 1B- immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new anti-migraine compounds. Cephalalgia. 17:1997;833-842.
30. Maassen VandenBrink A., van den Broek R.W.M., de Vries R., Saxena P.R. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan. Cephalalgia. 19:1999;398.
31. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 87:1993;401-405.
32. May A., Gijsman H.J., Wallnofer A., Jones R., Diener H.C., Ferrari M.D. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain. 67(2-3):1996;375-378.
33. 1D-like' receptor partial agonist. Cephalalgia. 17:1997;414.
34. 1B/1D-receptor agonist. Clin. Pharmacol. Ther. 66:1999;85-90.
35. 1D receptors. Eur. J. Pharmacol. 368:1999;259-268.
36. Nilsson T., Longmore J., Shaw D., Pantev E., Bard J.A., Branchek T., Edvinsson L. Characterisation of the 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol. 372:1999;49-56.
37. Norman B., Panebianco D., Block G.A. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia. 18:1998;407.
38. Ottervanger J.P., van Witsen T.B., Valkenburg H.A., Grobbee D.E., Stricker B.H. Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur. J. Clin. Pharmacol. 47:1994;305-309.
39. Pappagallo H., Szabo Z., Esposito G., Lokesh A., Velez L., Baltinoe N.D. Imaging neurogenic inflammation in patients with migraine headache. Neurology. 52(5):1999;S39.004. supplement 1.
40. 1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br. J. Pharmacol. 96:1989;434-440.
41. 1-like receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 346:1992;592-596.
42. 1F receptor agonist, in the neurogenic dural inflammation model of migraine pain. Soc. Neurosci. 22:1996;1331.
43. 1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 61:1997;2117-2126.
44. Pilgrim A.J., Blakeborough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev. Contemp. Pharmacother. 5:1994;295-309.
45. 1D receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;312-320.
46. 1F- receptor activation. Br. J. Clin. Pharmacol. 47:1999;75-82.
47. Roon K., Diener H.C., Ellis P., Hettiarachi J., Poole P., Christiansen I., Ferrari M.D., Olesen J. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical trials. Cephalalgia. 17:1997;245.
48. Saito K., Markowitz S., Moskowitz M.A. Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headache. Ann. Neurol. 24:1988;732-737.
49. 1D receptor agonists. Exp. Opin. Invest. Drugs. 5(5):1996;581-593.
50. 1B/1D receptor agonist with anti-migraine activity. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;212-219.
51. Willett F., Curzen N., Adams J., Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. Br. Med. J. 304:1992;1415. (see comments).
52. Williamson D.T., Shepheard S.L., Hill R.G., Hargreaves R.J. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol. 328:1997;61-64.